ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 007

Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

Emily Shuldiner 1, Elaine Remmers 2, Miranda Marion 3, Marc Sudman 4, Colleen Satorius 5, International Childhood Arthritis Genetics Consortium (INCHARGE), Juvenile Arthritis Consortium for the Immunochip (JACI), Wendy Thomson 6, Michael Ombrello1, Patricia Woo 7, Carl Langefeld 8, Sampath Prahalad 9 and Susan Thompson 10, 1NIAMS, NIH, Bethesda, 2National Human Genome Research Institute, Bethesda, 3Wake Forest University, Winston-Salem, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5NHGRI, NIH, Bethesda, 6Manchester Academic Health Science Centre, Manchester, United Kingdom, 7London, United Kingdom, 8Winston Salem, 9Emory + Children's Pediatric Institute, Atlanta, 10Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Chemokine Receptors, genetics, genomics, Systemic JIA

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Plenary Abstracts Session 3

Session Type: Plenary Session III

Session Time: 11:00AM-12:00PM

Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood arthritidies.  Despite recognition of excessive innate immune activation, specific host or environmental factors that underlie sJIA have eluded detection.  Genomic investigations are an important tool for identifying new disease associated genes and pathways, and recent genomic studies of sJIA have yielded important new insights.  Here, we examine sJIA with the Immunochip, a single nucleotide polymorphism (SNP) array that generates exceptionally dense genotyping at 186 immunogenetic loci, many of which are putatively relevant to sJIA.

Methods: Immunochip genotype data were generated in 889 sJIA cases from the International Childhood Arthritis Genetics Consortium and the Juvenile Arthritis Consortium for Immunochip and 16,144 geographically-matched control subjects.  All cases fulfilled the ILAR criteria for sJIA. Genotyping/genotype calling were performed according to the manufacturer’s protocols. The dataset was subjected to stringent quality control operations (QC) to exclude poor quality samples and markers. The study population was systematically restricted to subjects of northern European ancestry using principal components analysis (PCA). The full dataset was expanded with 1000 Genomes Project (1KG)-based SNP imputation.  Haplotypic analysis was performed for novel risk loci and association testing of markers and haplotypes was performed by logistic regression, corrected for sex and ancestry.  The effect of sJIA-associated variables on gene expression was examined in paired whole genome (WGS) and RNA sequencing data from lymphoblastoid cell lines (LCL) of 373 European 1KG subjects.

Results: SNP genotyping, imputation and QC produced a panel of 841,043 SNPs in a collection 579 sJIA cases and 12,930 healthy subjects of northern European ancestry (λGC=1.000). Association testing identified a novel, highly-significant susceptibility locus on chromosome 2 that contained CXCR4, encoding C-X-C chemokine receptor type 4. The strongest risk factor for sJIA in the study was a 124kb 6-SNP haplotype (case frequency 0.21, control frequency 0.13, p=4.3E-10, OR=1.7 [1.5, 1.9]). Analysis of paired WGS and RNAseq data identified positive correlation between the sJIA risk haplotype and CXCR4 expression in LCLs (p=4.0E-4).  Examination of the risk haplotype in public databases revealed that it 1) intersects with a lymphocyte super-enhancer that regulates CXCR4; and 2) engages in 3 distinct chromatin loops with the promoter of CXCR4 in LCLs.

Conclusion: This study has identified CXCR4 as a novel risk locus in sJIA. CXCR4 is an immunologically important molecule that is involved immune cell development and migration, particularly that of B lymphocytes.  The correlation of the sJIA risk haplotype with increased CXCR4 expression in LCLs, its intersection with a lymphocyte-specific super-enhancer and its formation of chromatin loops with the CXCR4 promoter in LCLs may indicate that this haplotype influences sJIA risk through B lymphocytes.  Further studies are necessary to systematically evaluate this hypothesis.


Disclosure: E. Shuldiner, None; E. Remmers, None; M. Marion, None; M. Sudman, None; C. Satorius, None; W. Thomson, None; M. Ombrello, None; P. Woo, None; C. Langefeld, None; S. Prahalad, None; S. Thompson, None.

To cite this abstract in AMA style:

Shuldiner E, Remmers E, Marion M, Sudman M, Satorius C, Thomson W, Ombrello M, Woo P, Langefeld C, Prahalad S, Thompson S. Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/dense-genotyping-of-immunologic-loci-identifies-cxcr4-as-a-novel-susceptibility-locus-for-systemic-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dense-genotyping-of-immunologic-loci-identifies-cxcr4-as-a-novel-susceptibility-locus-for-systemic-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology